🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock

Published 11/11/2024, 08:01 PM
PACB
-
CRSP
-
GH
-
U
-

Cathie Wood's ARK ETFs have disclosed their daily trades for Monday, November 11th, 2024, revealing a mix of strategic buys and sells across the technology and biotech sectors. Leading the sales was a significant reduction in Unity Software Inc (NYSE:U), with ARK divesting a total of 774,455 shares across its ARKK and ARKW ETFs, totaling approximately $15.88 million. This move comes after a series of recent sales in Unity stock by ARK, indicating a potential shift in the fund's investment strategy regarding the video game software company.

On the buying side, ARK's largest acquisition was in Pacific Biosciences (NASDAQ:PACB) of California Inc (NASDAQ:PACB), purchasing over a million shares across ARKK and ARKG ETFs, amounting to $2.32 million. This follows a pattern of accumulation in Pacific Biosciences, as ARK has consistently increased its position in the company over the past week, signaling strong confidence in the genetic sequencing firm.

Another notable trade included the purchase of 31,110 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) for a total of $1.61 million, split between ARKK and ARKG ETFs. This continues ARK's recent trend of bolstering its investment in the gene-editing company, which has seen multiple buy-ins from the fund over the last several days.

Guardant Health Inc (NASDAQ:GH) also saw an increase in ARK's holdings, with the purchase of 53,291 shares through its ARKG ETF, valued at approximately $1.52 million. This is in addition to the shares bought last Friday, suggesting a growing interest in the precision oncology company.

Other trades included a sell-off of 115,206 shares of Robinhood Markets Inc (NASDAQ:HOOD) across three ETFs (ARKK, ARKW, and ARKF), totaling around $3.52 million, and a sale of 41,984 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) through ARKG ETF, valued at $244,346.

Smaller transactions included the sale of 18,777 shares of Moderna Inc (NASDAQ:BMV:MRNA) and 885 shares of Materialise NV (NASDAQ:MTLS), with respective values of $879,326 and $5,947. On the buy side, ARK added 5,661 shares of Trade Desk Inc (NASDAQ:TTD), worth $708,360, and 40,822 shares of Illumina Inc (NASDAQ:ILMN), though the dollar value of the latter trade was not disclosed.

The report also noted sales of 18,096 shares of Repare Therapeutics Inc (NASDAQ:RPTX) and 397 shares of Senti Biosciences Inc (NASDAQ:SNTI), with values of $64,964 and $841, respectively. These daily trade details provide investors with a snapshot of ARK's latest investment maneuvers, offering insights into the fund's evolving market strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.